[{"id":"e544b76d-26e2-4ad6-a6eb-87395873bc91","acronym":"","url":"https://clinicaltrials.gov/study/NCT07085338","created_at":"2025-08-02T14:49:08.314Z","updated_at":"2025-08-02T14:49:08.314Z","phase":"Phase 2","brief_title":"A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma","source_id_and_acronym":"NCT07085338","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CSF2","pipe":"","alterations":" ","tags":["CSF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • irinotecan • Anktiva (nogapendekin alfa inbakicept-pmln) • Leukine (sargramostim) • humanised dinutuximab (Hu14.18K322A)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 02/01/2028","primary_completion_date":" 02/01/2028","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2025-07-25"},{"id":"056fe673-cdf1-43ac-850b-4889f543f569","acronym":"","url":"https://clinicaltrials.gov/study/NCT03169790","created_at":"2021-01-18T15:37:43.674Z","updated_at":"2025-02-25T12:26:42.620Z","phase":"Phase 1/2","brief_title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","source_id_and_acronym":"NCT03169790","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Rituxan (rituximab) • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • oxaliplatin • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-061 • NK92-CD16-158V • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 12/23/2021","study_completion_date":" 12/23/2021","last_update_posted":"2025-02-24"},{"id":"706663a7-a978-4e9d-b057-4930c92e0793","acronym":"","url":"https://clinicaltrials.gov/study/NCT05642195","created_at":"2022-12-08T15:58:15.185Z","updated_at":"2025-02-25T12:29:14.210Z","phase":"Phase 1/2","brief_title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05642195","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln) • H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant"],"overall_status":"Suspended","enrollment":" Enrollment 30","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 12/30/2033","primary_completion_date":" 12/30/2033","study_txt":" Completion: 12/30/2035","study_completion_date":" 12/30/2035","last_update_posted":"2025-02-24"},{"id":"1f7645ce-b871-4582-a76b-ca5622eeebeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05419011","created_at":"2022-06-15T16:54:47.107Z","updated_at":"2025-02-25T13:41:05.612Z","phase":"Phase 2","brief_title":"Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome","source_id_and_acronym":"NCT05419011","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":"","alterations":" ","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 05/08/2023","start_date":" 05/08/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-21"},{"id":"44d24989-a21f-4511-a498-f631f60a4181","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554109","created_at":"2021-01-18T17:29:18.298Z","updated_at":"2025-02-25T13:39:37.796Z","phase":"Phase 2","brief_title":"QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine","source_id_and_acronym":"NCT03554109","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Bavencio (avelumab) • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2018","start_date":" 09/01/2018","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 02/09/2022","study_completion_date":" 02/09/2022","last_update_posted":"2025-02-21"},{"id":"412de90b-4e3b-4146-9e47-4f34d9a4603a","acronym":"QUILT-3.055","url":"https://clinicaltrials.gov/study/NCT03228667","created_at":"2021-01-18T15:56:08.764Z","updated_at":"2025-02-25T17:35:53.589Z","phase":"Phase 2","brief_title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT03228667 - QUILT-3.055","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" BRAF • ALK • MSI","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type","tags":["BRAF • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/11/2018","start_date":" 12/11/2018","primary_txt":" Primary completion: 08/31/2029","primary_completion_date":" 08/31/2029","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-01-29"},{"id":"2eaae65f-9d42-467a-af85-4f3db4d060b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04847466","created_at":"2021-04-19T12:52:34.726Z","updated_at":"2024-07-02T16:34:25.971Z","phase":"Phase 2","brief_title":"Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer","source_id_and_acronym":"NCT04847466","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" HER-2 positive","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-14"},{"id":"dbc8831d-81b1-4462-a1b5-6692494a1c38","acronym":"","url":"https://clinicaltrials.gov/study/NCT06253494","created_at":"2024-02-12T17:27:19.601Z","updated_at":"2024-07-02T16:34:25.860Z","phase":"Phase 1/2","brief_title":"Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer","source_id_and_acronym":"NCT06253494","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Suspended","enrollment":" Enrollment 60","initiation":"Initiation: 05/14/2024","start_date":" 05/14/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-06-14"},{"id":"786f4600-19b5-4661-828d-06dd8c75ce47","acronym":"QuEST1","url":"https://clinicaltrials.gov/study/NCT03493945","created_at":"2021-12-08T18:56:16.054Z","updated_at":"2024-07-02T16:34:37.137Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","source_id_and_acronym":"NCT03493945 - QuEST1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • BRCA1 • BRCA2 • MSI • HRD","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • BRCA1 • BRCA2 • MSI • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • epacadostat (INCB024360) • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 05/01/2018","start_date":" 05/01/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-07"},{"id":"404cec14-59ad-4bad-8ff9-682424e0a253","acronym":"","url":"https://clinicaltrials.gov/study/NCT06061809","created_at":"2023-09-29T19:11:27.420Z","updated_at":"2024-07-02T16:35:00.558Z","phase":"Phase 2","brief_title":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","source_id_and_acronym":"NCT06061809","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" IL6 • TNFA","pipe":"","alterations":" ","tags":["IL6 • TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/17/2024","start_date":" 07/17/2024","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2024-05-29"},{"id":"7bef29a7-07ed-4332-9706-9ee664c0f131","acronym":"Lung-MAP Non-Match Sub-Study","url":"https://clinicaltrials.gov/study/NCT05096663","created_at":"2021-10-27T14:53:21.327Z","updated_at":"2024-07-02T16:35:05.962Z","phase":"Phase 2/3","brief_title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT05096663 - Lung-MAP Non-Match Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion","tags":["EGFR • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln) • Hemady (dexamethasone tablets) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-03"},{"id":"b7dbd59d-0e5c-48d1-85e5-f28fb24a008f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445882","created_at":"2022-07-06T14:54:26.168Z","updated_at":"2024-07-02T16:35:11.811Z","phase":"Phase 2","brief_title":"N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT05445882","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-04-02"},{"id":"6b5589c3-59a6-45f6-974c-041f3dc119f7","acronym":"QUILT2023","url":"https://clinicaltrials.gov/study/NCT03520686","created_at":"2021-01-18T17:20:07.266Z","updated_at":"2024-07-02T16:35:20.505Z","phase":"Phase 3","brief_title":"QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.","source_id_and_acronym":"NCT03520686 - QUILT2023","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" EGFR • PD-L1 • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1538","initiation":"Initiation: 05/18/2018","start_date":" 05/18/2018","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-02-07"},{"id":"ce910ebc-2111-40c9-8011-63c73b539176","acronym":"","url":"https://clinicaltrials.gov/study/NCT04898543","created_at":"2021-05-24T15:53:54.007Z","updated_at":"2024-07-02T16:35:22.660Z","phase":"Phase 1","brief_title":"QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04898543","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" CD4 • NKG2D","pipe":"","alterations":" ","tags":["CD4 • NKG2D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln) • m-ceNK cells"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/21/2021","start_date":" 06/21/2021","primary_txt":" Primary completion: 06/21/2024","primary_completion_date":" 06/21/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-23"},{"id":"022a29da-b197-4827-a622-2e8a2fce79e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04491955","created_at":"2021-01-18T21:34:47.909Z","updated_at":"2024-07-02T16:35:29.342Z","phase":"Phase 2","brief_title":"Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers","source_id_and_acronym":"NCT04491955","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CEACAM5 • CD4","pipe":"","alterations":" ","tags":["CEACAM5 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/22/2020","start_date":" 09/22/2020","primary_txt":" Primary completion: 10/25/2022","primary_completion_date":" 10/25/2022","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-11-14"},{"id":"a530d193-d51c-4599-96ac-93716c7318aa","acronym":"QUILT-3.067","url":"https://clinicaltrials.gov/study/NCT03387085","created_at":"2021-01-18T16:42:58.165Z","updated_at":"2024-07-02T16:35:35.512Z","phase":"Phase 1/2","brief_title":"QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.","source_id_and_acronym":"NCT03387085 - QUILT-3.067","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • 5-fluorouracil • Bavencio (avelumab) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-011 • ETBX-051 • ETBX-061 • GI-4000 • GI-6207 • GI-6301 • NK92-CD16-158V • aldoxorubicin (INNO-206)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-09-27"},{"id":"5721131c-9952-4fea-aa7e-d82fdc96bfa7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02523469","created_at":"2021-01-18T12:12:03.653Z","updated_at":"2024-07-02T16:35:53.847Z","phase":"Phase 1/2","brief_title":"ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02523469","lead_sponsor":"Medical University of South Carolina","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 01/08/2016","start_date":" 01/08/2016","primary_txt":" Primary completion: 02/24/2023","primary_completion_date":" 02/24/2023","study_txt":" Completion: 02/24/2023","study_completion_date":" 02/24/2023","last_update_posted":"2023-03-07"},{"id":"e563983d-59ef-4c13-a972-23c5f2266842","acronym":"","url":"https://clinicaltrials.gov/study/NCT02890758","created_at":"2021-01-18T14:11:18.504Z","updated_at":"2024-07-02T16:35:55.216Z","phase":"Phase 1","brief_title":"Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803","source_id_and_acronym":"NCT02890758","lead_sponsor":"Brenda Cooper, MD","biomarkers":" ABL1 • BCR • NCAM1","pipe":" | ","alterations":" NCAM1 positive","tags":["ABL1 • BCR • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 05/22/2018","start_date":" 05/22/2018","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 02/17/2023","study_completion_date":" 02/17/2023","last_update_posted":"2023-02-20"},{"id":"9ea61dc8-02d1-4a21-bd49-3ef6ea8e27c0","acronym":"RAN","url":"https://clinicaltrials.gov/study/NCT05007769","created_at":"2021-08-16T16:54:48.785Z","updated_at":"2024-07-02T16:36:21.100Z","phase":"Phase 2","brief_title":"Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC","source_id_and_acronym":"NCT05007769 - RAN","lead_sponsor":"Washington University School of Medicine","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cyramza (ramucirumab) • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/31/2021","start_date":" 10/31/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2021-11-05"},{"id":"a0d7adfd-bd4d-4476-a063-6c04cc35ce76","acronym":"","url":"https://clinicaltrials.gov/study/NCT03003728","created_at":"2021-01-18T14:46:32.775Z","updated_at":"2025-02-25T14:37:04.983Z","phase":"Phase 2","brief_title":"2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)","source_id_and_acronym":"NCT03003728","lead_sponsor":"University of Arkansas","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • Empliciti (elotuzumab) • Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 07/08/2020","primary_completion_date":" 07/08/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2020-07-10"},{"id":"d9d4f5b6-6160-4feb-bae6-c40ed4282553","acronym":"","url":"https://clinicaltrials.gov/study/NCT01946789","created_at":"2021-01-18T08:49:34.489Z","updated_at":"2024-07-02T16:37:00.469Z","phase":"Phase 1","brief_title":"A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01946789","lead_sponsor":"Altor BioScience","biomarkers":" EGFR • BRAF • ALK","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • ALK rearrangement","tags":["EGFR • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 08/01/2017","primary_completion_date":" 08/01/2017","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2019-04-17"},{"id":"6e2bc0cd-0b27-4b8b-b4cf-d2d75c0f287a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03365661","created_at":"2021-01-18T16:36:35.414Z","updated_at":"2024-07-02T16:37:05.437Z","phase":"Phase 2","brief_title":"QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML","source_id_and_acronym":"NCT03365661","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" TP53 • FLT3 • KIT • DNMT3A • RUNX1 • ASXL1 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • FLT3 mutation • KIT mutation • DNMT3A mutation • ASXL1 mutation","tags":["TP53 • FLT3 • KIT • DNMT3A • RUNX1 • ASXL1 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • FLT3 mutation • KIT mutation • DNMT3A mutation • ASXL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2018-11-09"},{"id":"90f18f7f-c4e4-4527-ac5a-731657a938be","acronym":"QUILT-3.005","url":"https://clinicaltrials.gov/study/NCT02099539","created_at":"2022-05-31T23:56:09.671Z","updated_at":"2024-07-02T16:37:14.554Z","phase":"Phase 1/2","brief_title":"QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT02099539 - QUILT-3.005","lead_sponsor":"Altor BioScience","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anktiva (nogapendekin alfa inbakicept-pmln)"],"overall_status":"Unknown status","enrollment":" Enrollment 18","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2018-01-23"}]